Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

{2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-d-Glucose} suppresses proliferation and induces apoptosis in the human esophageal cancer cell line

Authors: Jing Wu, Hong Lu, Xiangchun Ling, Canghai Wang, Ji Rui, Aiqin Wang, Liang Qiao

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

The aim of this study was to investigate the molecular mechanisms of apoptosis induced by {2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-d-Glucose} (COPADG) in the esophageal cancer cell line Eca-109 and to establish a relationship between the rate of apoptosis and Fas and Bcl-2 protein expression. Eca-109 cells were cultured under standard condition. Cell growth was measured by MTT assay. Apoptosis and cell proliferation were determined by flow cytometry. Expressions of apoptosis-regulated genes Fas and Bcl-2 were detected by immunohistochemical methods and image analysis. COPADG dose- and time-dependently inhibited the growth of Eca-109 cells in vitro. Incubation of Eca-109 cells with 40 μmol/l of COPADG for 48 h induced significant apoptosis. After drug treatment, Fas protein expression was increased, while Bcl-2 protein expression was decreased. COPADG is able to induce apoptosis in the esophageal cancer cell line Eca-109. The mechanism of apoptosis in these cells may be related to up-regulation of Fas gene expression and the down-regulation of Bcl-2, which may serve as the experimental evidence for development of new drugs for the non-surgical management of human esophageal cancer.
Literature
1.
go back to reference Wu J, Lu H, Zhou Y, Qiao L, Ji R, Wang A-Q, et al. Effect of 2-(3-carboxy-1-oxopropyl) amino-2-deoxy-D-glucose on human esophageal cancer cell line. World J Gastroenterol. 2004;10:3380–1.PubMed Wu J, Lu H, Zhou Y, Qiao L, Ji R, Wang A-Q, et al. Effect of 2-(3-carboxy-1-oxopropyl) amino-2-deoxy-D-glucose on human esophageal cancer cell line. World J Gastroenterol. 2004;10:3380–1.PubMed
2.
go back to reference Wu J, Wei K, Wang A-Q, Liu W-M, Xue Q-J, Qiao L. Effects of 2-[(3-carboxy-1-oxoprogy1) amino]-2-deoxy-D-Glucose on human hepatocellular carcinoma cell line. Acta Pharmacol Sin. 2005;26:635–40.PubMedCrossRef Wu J, Wei K, Wang A-Q, Liu W-M, Xue Q-J, Qiao L. Effects of 2-[(3-carboxy-1-oxoprogy1) amino]-2-deoxy-D-Glucose on human hepatocellular carcinoma cell line. Acta Pharmacol Sin. 2005;26:635–40.PubMedCrossRef
3.
go back to reference Zhe Wang, Yan Qiao, Huang Gao-Sheng. Glucosamine and glucosamine hydrochloride induced leukemia cell line K562 differentiation into macrophage. Chin Pharacological Bulletin. 2003;19:290–3. Zhe Wang, Yan Qiao, Huang Gao-Sheng. Glucosamine and glucosamine hydrochloride induced leukemia cell line K562 differentiation into macrophage. Chin Pharacological Bulletin. 2003;19:290–3.
4.
go back to reference Wang Z, Qiao Y, Huang G-S. Induction of macrophagic differentiation of leukemia cell line K562 by N-acetyl-D-glucosamine. J Fourth Mil Med Uni. 2003;24:46–8. Wang Z, Qiao Y, Huang G-S. Induction of macrophagic differentiation of leukemia cell line K562 by N-acetyl-D-glucosamine. J Fourth Mil Med Uni. 2003;24:46–8.
5.
go back to reference Xie Q, Dai Y, Sun F. The morphology of melanoma induced by glucosamine hydrochloride. J Anhui TCM College. 2002;21:42–4. Xie Q, Dai Y, Sun F. The morphology of melanoma induced by glucosamine hydrochloride. J Anhui TCM College. 2002;21:42–4.
6.
go back to reference Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18:240–4.PubMedCrossRef Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18:240–4.PubMedCrossRef
7.
go back to reference Cohen J. Apoptosis: Mechanisms of life and death in the immune system. J Allergy Clin Immunol. 1999;103:548–54.PubMedCrossRef Cohen J. Apoptosis: Mechanisms of life and death in the immune system. J Allergy Clin Immunol. 1999;103:548–54.PubMedCrossRef
8.
go back to reference Von Reyher U, Strater J, Kittstein W. Colon carcinoma cells use different mechanisms to escape CD95 mediated apoptosis. Cancer Res. 1998;58:526–34. Von Reyher U, Strater J, Kittstein W. Colon carcinoma cells use different mechanisms to escape CD95 mediated apoptosis. Cancer Res. 1998;58:526–34.
9.
go back to reference Nambu Y, Hughes SJ, Rehemtulla A. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998;101:1102–10.PubMedCrossRef Nambu Y, Hughes SJ, Rehemtulla A. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998;101:1102–10.PubMedCrossRef
10.
go back to reference Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces Fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology. 2000;59:336–43.PubMedCrossRef Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces Fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology. 2000;59:336–43.PubMedCrossRef
11.
go back to reference Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res. 1999;5:2464–9.PubMed Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res. 1999;5:2464–9.PubMed
12.
go back to reference Younes M, Lechago J, Ertan A, Finnie D, Younes A. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett’s esophagus. Hum Pathol. 2000;31:434–8.PubMedCrossRef Younes M, Lechago J, Ertan A, Finnie D, Younes A. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett’s esophagus. Hum Pathol. 2000;31:434–8.PubMedCrossRef
13.
go back to reference Kase S, Osaki M, Adachi H, Kaibara N, Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol. 2002;20:291–7.PubMed Kase S, Osaki M, Adachi H, Kaibara N, Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol. 2002;20:291–7.PubMed
14.
go back to reference Sarbia M, Bittinger F, Porschen R. Bcl-2 expression and prognosis in squamous cell carcinoma of the esophagus. Int J Cancer. 1996;69:324–8.PubMedCrossRef Sarbia M, Bittinger F, Porschen R. Bcl-2 expression and prognosis in squamous cell carcinoma of the esophagus. Int J Cancer. 1996;69:324–8.PubMedCrossRef
15.
go back to reference Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, Reynolds JV. Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 2003;16:17–23.PubMedCrossRef Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, Reynolds JV. Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 2003;16:17–23.PubMedCrossRef
16.
go back to reference Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Chen JT. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma. 2001;48:483–8.PubMed Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Chen JT. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma. 2001;48:483–8.PubMed
Metadata
Title
{2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-d-Glucose} suppresses proliferation and induces apoptosis in the human esophageal cancer cell line
Authors
Jing Wu
Hong Lu
Xiangchun Ling
Canghai Wang
Ji Rui
Aiqin Wang
Liang Qiao
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9585-1

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.